SCHEMBL570064

SCHEMBL570064

COC(=O)c1cc([N+](=O)[O-])ccc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
HTT P42858 3/20 0.56
PKM P14618 1/20 0.56
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
LMNA P02545 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KCNMA1 Q12791 1/20 0.53
MAPT P10636 2/20 0.53
POLB P06746 3/20 0.53
NPC1 O15118 1/20 0.53
MAPK1 P28482 2/20 0.52
CTSV O60911 1/20 0.52
CTSL P07711 1/20 0.52
BLM P54132 1/20 0.52
ALDH1A1 P00352 1/20 0.52
RORC P51449 1/20 0.52
CYP19A1 P11511 1/20 0.51
PTGS2 P35354 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9234021 0.90 ALDH1A1 (0.52) TDP1HTTPKMMEN1KMT2A
SCHEMBL4831527 0.88 MAPT (0.52) TDP1HTTPKMMEN1KMT2A
SCHEMBL27547838 0.88 ALDH1A1 (0.50) TDP1HTTPKMMEN1KMT2A
SCHEMBL656472 0.87 HTT (0.60) TDP1HTTPKMMEN1KMT2A
SCHEMBL10605482 0.86 RECQL (0.51) TDP1HTTPKMMEN1KMT2A
SCHEMBL178001 0.86 TDP1 (0.52) TDP1HTTPKMMEN1KMT2A
SCHEMBL6587408 0.86 CTSV (0.58) TDP1HTTPKMMEN1KMT2A
SCHEMBL18722763 0.85 KDM4E (0.45) HTTPKMMEN1KMT2ALMNA
SCHEMBL1671926 0.85 CTSV (0.60) TDP1HTTPKMMEN1KMT2A
SCHEMBL15486505 0.85 TDP1 (0.58) TDP1HTTPKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO, INC. 2025-06-12 US disclosed
CN-115515685-B EIF4E inhibitors and uses thereof 皮克医疗公司 2025-04-08 CN disclosed
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 US disclosed
US-12133852-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2024-11-05 US disclosed
WO-2024030651-A1 GPX4 INHIBITORS AND USE THEREOF SONATA THERAPEUTICS, INC. (US) 2024-02-08 WO disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
WO-1997030990-A1 NOVEL SUBSTITUTED N-METHYL-N-(4-(PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-08-28 WO disclosed
WO-1997030989-A1 NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-08-28 WO disclosed
WO-1997022604-A1 NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-06-26 WO disclosed
WO-1997019074-A1 SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-05-29 WO disclosed
EP-0675886-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-10-11 EP disclosed
US-5382590-A Gastrointestinal disorders and nervous system disorders RHONE-POULENC RORER S.A. (FR) 1995-01-17 US disclosed
WO-1994013663-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO disclosed
EP-0148752-B1 PROTEASE INHIBITORS G.D. Searle & Co. (US) 1989-06-21 EP disclosed
US-4551279-A Protease inhibitors G. D. SEARLE & CO. (US) 1985-11-05 US disclosed
EP-0148752-A2 Protease inhibitors G.D. Searle & Co. (US) 1985-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 TDP1 3649/4885HTT 4784/4885PKM 833/4885
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885HTT 1458/4885PKM 1204/4885
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885HTT 1458/4885PKM 1204/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885HTT 1458/4885PKM 1204/4885
US-12133852-B2 ACSS2 inhibitors and methods of use thereof ACSS2, GLS2, ADSS2 TDP1 3649/4885HTT 4784/4885PKM 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.